辉瑞称一名参与血友病药物Hympavzi长期研究的患者死亡

Core Viewpoint - Pfizer reported the death of a patient involved in a long-term study of its hemophilia drug Hympavzi, which raised concerns about the safety of the treatment [1] Group 1: Incident Details - The patient experienced severe side effects leading to death during the clinical trial [1] - Pfizer is actively gathering information in collaboration with trial researchers and an independent external data monitoring committee to understand the complexities surrounding the incident [1] Group 2: Drug Information - Hympavzi is a weekly injection therapy aimed at preventing or reducing bleeding episodes in patients aged 12 and older with Type A or B hemophilia [1] - Pfizer stated that based on current information and overall clinical data collected so far, the drug is not expected to pose any safety risks to treated patients [1]